artemether / Generic mfg. - LARVOL DELTA

Artemether as a modulator of EMT in colorectal cancer: enhancing radiosensitivity and reversing chemo-radiation resistance. (PubMed, BMC Gastroenterol) - "These findings provide both mechanistic insights and experimental validation for the potential application of ARE as a radiosensitizer in colorectal cancer radiotherapy."

Journal • Colorectal Cancer • Oncology • Solid Tumor • Transplantation • CDH1 • CDH2 • CTNNB1 • SNAI2 • VIM

Successful treatment of severe cerebral malaria with artificial liver blood purification technology: A case report. (PubMed, Medicine (Baltimore)) - "The integration of artificial liver blood purification with continuous renal replacement therapy may serve as an effective rescue therapy for severe malaria with multi-organ failure, potentially by mitigating the systemic inflammatory response and supporting organ recovery. This case highlights the potential of combined extracorporeal support in managing critical tropical infections."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Liver Failure • Malaria • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Septic Shock • Systemic Inflammatory Response Syndrome • Thrombocytopenia

Anti-Theileria equi activity of methanolic extract of Artemisia scoparia: In vitro efficacy, in vivo safety, and identification of lead molecules. (PubMed, Vet Parasitol) - "HPLC and LC-MS/MS analyses identified 17 bioactive compounds in MF-ASME, with artemisinin, artemether, and dihydroartemisinin as the primary antimalarial agents. These results support the potential of MF-ASME for further therapeutic development against equine theileriosis."

Journal • Preclinical • Infectious Disease

Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation. (PubMed, Biochem Pharmacol) - "Through a high-throughput screen of FDA-approved compounds, artemether (ART) emerged as a robust inducer of PD-L1 surface expression in multiple murine and human TNBC cell lines. Critically, in syngeneic TNBC mouse models, ART synergistically enhanced the antitumor efficacy of atezolizumab, promoting tumor regression and increasing intratumoral CD8+ T cell infiltration and cytotoxicity. Our findings reveal a novel mechanism by which ART upregulates PD-L1 through KEAP1 inhibition and establish ART as a promising pharmacological agent to improve the clinical outcomes of PD-L1 checkpoint blockade immunotherapy in TNBC."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Triple Negative Breast Cancer • CD8 • KEAP1 • PD-L1

Effect of artesunate and artemether against Opisthorchis felineus in rodent model. (PubMed, Acta Trop) - "A comparative in vivo assessment of the artemisinin derivatives artesunate and artemether (150 and 300 mg/kg) and praziquantel (400 mg/kg) was conducted in a hamster model of opisthorchiasis caused by Opisthorchis felineus. Administration of artesunate and artemether at both doses normalized platelet, eosinophil, and basophil counts in infected animals. The results indicate that artemisinin derivatives may serve as promising alternatives for the treatment of O. felineus opisthorchiasis and warrant further preclinical and clinical evaluation."

Journal • Preclinical • Hematological Disorders • Infectious Disease

Artemether Attenuates High Glucose-Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF-β/Smad Pathway Via PPARγ Activation. (PubMed, J Diabetes Res) - "In conclusion, our study indicates that Art protects renal tubular epithelial cells by partially modulating PPARγ-dependent inhibition of the TGF-β/Smad pathway, thereby mitigating HG-induced inflammation and fibrosis. These findings suggest that Art holds promising therapeutic potential for DKD treatment."

Journal • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Infectious Disease • Inflammation • Malaria • Nephrology • Oncology • Renal Disease • IL1B • IL6 • PPARG • TGFB1 • TNFA

Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer. (PubMed, Front Pharmacol) - "Specifically, in phase of inflammation and injury (phase Ⅰ), artesunate, dihydroartemisinin, and artemether alleviate the symptoms of pneumonia and lung injury by regulating inflammatory responses, oxidative stress, apoptosis, and endoplasmic reticulum stress...Additionally, current research is focused on nanoscale delivery systems to increase the bioavailability and improve drug stability, to enhance the therapeutic efficacy of these compounds. Collectively, artemisinin and its derivatives are the potential clinically useful therapeutic agents for protecting lungs and hampering the dynamic development processes of lung diseases to lung cancer."

Journal • Review • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • KEAP1

Comparative effects of antimalarial drugs on oxidative phosphorylation, mitochondrial dynamics and mitophagy in Plasmodium berghei-infected mice. (PubMed, Toxicol Rep) - "Thirty-five Swiss-mice (18 ± 3 g) were infected intraperitoneally with chloroquine resistant (ANKA) strain of Plasmodium berghei and treated orally and once daily with (10 mg/kg) dose of Amodiaquine artesunate (AA), Artemether-Lemefantrine (AL), Sulfadoxine- pyrimethamine (SP) and Artesunate (ART), On day 6, animals were sacrificed and livers were removed. Significant down-regulation in the expressions of PINK 1 by SP, FUNDC1 by AA and AL, DNM1L by ART, PGC-1α by AA, AL, and ART, and prohibitins 1 and 2 by AA and AL similar to the infected control were observed. This study showed that host mitochondria respond differently to antimalarial drugs."

Journal • Preclinical • Infectious Disease • MFN2

The contrasting effects of two antimalarial drugs on insulin secretion. (PubMed, Cell Mol Life Sci) - "In particular, artemether significantly suppressed insulin secretion, decreased Ca2+ influx and the expression levels of β-cell marker genes, contradicting the findings of previous studies suggesting that artemisinins promote the transformation of pancreatic α cells into β cells. Overall, our observations revealed the differential effects of two widely used antimalarial drugs, quinolines and artemisinins, on insulin secretion. Ascertaining the targets by which drugs affect insulin secretion may advance diabetes treatment."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Malaria • Metabolic Disorders

Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis. (PubMed, J Cosmet Dermatol) - No abstract available

Journal • Dermatitis • Dermatology • Immunology • Seborrheic Dermatitis

β-Dystroglycan Downregulation and Astrocytic Alterations: A Possible Role in Blood-Brain Barrier Disruption During Experimental Cerebral Malaria. (PubMed, Mol Neurobiol) - "Early treatment with artemether (ARM) was conducted to monitor the recovery during pathology...Furthermore, immunohistochemical analysis revealed loss of β-dystroglycan (β-DG), altered astrocyte morphology, and reduced tight junction protein zonula occludens-1 (ZO-1) and collagen IV expression during disease. In summary, these results suggested that β-DG cleavage by matrix metalloproteinase-9 (MMP-9) results in the disruption of astrocytic cellular connection with vasculature, and when dystrophin-glycoprotein complex (DGC) proteins are dysregulated, it leads to the development of edema."

Journal • CNS Disorders • Infectious Disease • Malaria • MMP9 • TJP1

Pharmacogenomics in Orofacial Clefts Care: Insights from Whole-Genome Sequencing of Case-Parents Trios. (PubMed, J Pers Med) - "The identified variations were linked to the metabolism of frequently used pharmaceuticals in Africa, such as caffeine, ketoconazole, efavirenz, carbamazepine, and artemether. These findings highlight the need for pharmacogenetic screening to inform personalized medicine, diminish ADRs, and enhance the clinical care of OFCs in Sub-Saharan Africa."

Biomarker • Journal • ABCC3 • CYP1A2 • CYP27A1

Identification of a novel locus associated with decreased susceptibility of Plasmodium falciparum to lumefantrine and artemisinin in Uganda (ASTMH 2025) - "The most common artemisinin-based combination (ACT), artemether-lumenantrine, is threatened in Uganda, where multiple artemisinin partial resistance (ART-R) mutations in Kelch13 (K13), including the C469Y and A675V mutations, are spreading, and decreasing lumefantrine (LUM) susceptibility has been demonstrated...PIN-carrying isolates showed significantly decreased ex vivo susceptibility to LUM, mefloquine and dihydroartemisinin (DHA) compared to WT (P<0.0001 for each drug). The newly identified PIN haplotype represents a candidate marker for decreased susceptibility to DHA and/or LUM. Its rapid spread in Uganda underscores the importance of evaluating its distribution and role in the emergence of ART-R elsewhere in East Africa."

Late-breaking abstract • Infectious Disease

Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. (PubMed, Br J Clin Pharmacol) - "The DDI effect of amodiaquine on the pharmacokinetics of artemether-lumefantrine is expected to be minimal, the based on the current analysis. However, further large-scale clinical trials are needed to confirm this finding."

Journal • PK/PD data • Infectious Disease • Malaria

Arterolane and Piperaquine Vs. Artemether and Lumefantrine in Uncomplicated Malaria: A Randomized Study in Nigeria. (PubMed, Int J Infect Dis) - "Once-daily dosing of AMP demonstrates comparable efficacy and safety to standard twice-daily dosing of AL in the treatment of uncomplicated P. falciparum malaria."

Journal • Infectious Disease • Malaria

Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis. (PubMed, J Cosmet Dermatol) - "The 0.063% artemether shampoo has comparable clinical efficacy to the 2% ketoconazole shampoo in the treatment of SD, and may exhibit stronger anti-inflammatory effects."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Seborrheic Dermatitis • CXCL8 • IL17A • IL1B • NFKB1

Discovery of novel Plasmodium falciparum PfDHFR-TS inhibitors from ConMedNP natural compounds: a multi-computational approach. (PubMed, Mol Divers) - "DFT analysis highlighted CA0001's reactivity as a soft electrophile, contrasting with artemether's higher reactivity. This comprehensive approach integrating docking, QSAR, DFT, and MD positions CA0001 as a promising PfDHFR-TS inhibitor alongside artemether, with ConMedNP and predictive models guiding future experimental validation."

Journal • Infectious Disease • DHFR • TYMS

Artemether ameliorates type 1 diabetes mellitus by modulating glycolipid metabolism in skeletal muscle. (PubMed, Am J Transl Res) - "Artemether treatment inhibited pyruvate dehydrogenase kinase 4 activity and activated pyruvate dehydrogenase, promoting aerobic glucose metabolism and suppressing fatty acid metabolism in skeletal muscle. These findings suggest that artemether can alleviate symptoms in T1D mice by modulating glycolipid metabolism in skeletal muscle."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Type 1 Diabetes Mellitus • PDK4

Efficacy of Anti-Toxoplasma Medications in Symptom Severity and Cognition in Patients with Schizophrenia or Schizoaffective Disorder: Systematic Review and Meta-analysis. (PubMed, Braz J Psychiatry) - "Anti-Toxoplasma antibiotics may offer potential benefits as adjunctive therapy for schizophrenia. However, heterogeneity and methodological limitations complicate conclusions. Large-scale RCTs are needed further to clarify the role of anti-Toxoplasma antibiotics in schizophrenia treatment."

Journal • Retrospective data • CNS Disorders • Infectious Disease • Psychiatry • Schizophrenia

Acetyl-CoA synthetase mutations affect the susceptibility of Plasmodium falciparum to antimalarial drugs. (PubMed, Microbiol Spectr) - "The results demonstrated that PfAcAS S868G and V950I mutations alone or in combination affected the susceptibility of P. falciparum to several antimalarial drugs, including the artemisinin derivatives (dihydroartemisinin, artesunate, and artemether) and chloroquine, although absolute changes in susceptibilities were modest.IMPORTANCEMalaria, an infectious disease caused by Plasmodium parasites and transmitted by mosquitoes, continues to be one of the most pressing public health challenges worldwide. In this study, we performed whole-genome sequencing analysis on P. falciparum strains that reemerged following ACT treatment. We aim to identify molecules potentially associated with drug resistance, which may provide new molecular markers for monitoring drug resistance in P. falciparum."

Journal • Infectious Disease • Malaria

Comparison of Artemether Versus Quinine for the Treatment of Cerebral Malaria in Children: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "In summary, artemether demonstrated a mildly superior efficacy in comparison to quinine. Thus, regions with artemisinin-sensitive strains of malaria are encouraged to continue the use of artemisinin; however, regions with artemisinin resistance may consider the use of quinine as an alternative in the treatment of cerebral malaria in children. Future comprehensive randomized controlled studies are needed to arrive at a robust conclusion."

Journal • Retrospective data • Review • Infectious Disease • Malaria

Formulation development and optimization of artemether-lumefantrine self-nanoemulsifying drug delivery systems. (PubMed, Pharmazie) - "Compatibility studies revealed no prominent or significant incompatibilities between the drugs and selected excipients. The optimized formulation was stable as dispersions with nano-sized droplets and a loading capacity >99 % for both ART and LMF and a release >95% within 15 min for both drugs, reflecting a significant increase in the rate and extent of dissolution compared to that of the pure drug."

Journal

A comprehensive review of artesunate-induced organ toxicity: mechanisms, resistance, biomarkers, and protective strategies. (PubMed, Drug Chem Toxicol) - "Overall, this paper underscores the need for more comprehensive research, including well-designed clinical trials, to better understand and manage the potential toxic effects of ART. Strengthening this knowledge is essential to ensure that the risk of organ damage does not compromise the life-saving benefits of malaria treatment."

Biomarker • Journal • Review • Infectious Disease • Inflammation • Malaria

Polycyclitol Derivatives Restore Long- Term Memory Via cdk5/p25 Activation of Tau Signaling in Experimental Cerebral Malaria. (PubMed, Neurochem Res) - "In this study, we employed an experimental cerebral malaria model to assess the therapeutic potential of four polycyclic derivatives, SR4-01 to SR4-04, as adjuncts to artemether...Western blot analysis confirmed reduced Cdk5-p25-mediated tau phosphorylation in the SR4-04 treated group. Collectively, our findings suggest that SR4-02 and SR4-04 hold promise as adjunctive therapies for reducing tau pathology and restoring cognitive function in cerebral malaria-associated neurodegeneration."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Infectious Disease • Malaria • CA3 • IL1B

Multi-target regulation by artemether in MAFLD through EGFR/HSP90 pathways. (PubMed, J Adv Res) - "These findings identify EGFR as a key target of Art, modulated directly or via HSP90, thereby offering new insights into Art's multi-target therapeutic mechanism in MAFLD."

Journal • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • CDC37 • EGFR • HSP90AA1